American Journal

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
Tuesday, April 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.

The American Journal of Managed Care® (AJMC®)’s Institute for Value-Based Medicine® (IVBM®) hosts event to highlight treatment options for obesity and minimizing risk of type 2 diabetes and cardiovascular disease

Retrieved on: 
Friday, April 5, 2024
American Heart Association, Cardiovascular disease, Obesity, Public health, UH, Type 2 diabetes, Risk, Partnership, DSM-IV codes, Integration, Harvard University, American Journal, Central nervous system, Diabetes, Health, Research, Travel, Neuroendocrinology, Role, Doctor of Public Health, MBA, WTW, Campbell University, CINEMA, MSL

The Institute for Value-Based Medicine® (IVBM®) has gained recognition for advocating value-based care and advancing health care methodologies.

Key Points: 
  • The Institute for Value-Based Medicine® (IVBM®) has gained recognition for advocating value-based care and advancing health care methodologies.
  • The upcoming event will showcase a panel of health care experts engaging in discussions about the latest advancements in the fields of value-based care and population health practices.
  • The event aims to acknowledge and explore the challenges within these domains.
  • Their invaluable insights and contributions will enrich the event, making it an exceptional platform for cutting-edge discussions in the health care landscape.

Beyond Meat® Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart Association’s Heart-Check Program and the American Diabetes Association’s Better Choices for Life Program

Retrieved on: 
Thursday, March 28, 2024
American Heart Association, Health, LDL, Certification, Cardiovascular disease, Taste, BYND, Nutrition, TMAO, Nutrient, Diabetes, American Journal, American Cancer Society, Stroke, Crumble, Beyond Meat, Sodium, Food, Death, Risk, Breakfast, Diet, American Diabetes Association, Beyond, Reference Daily Intake, Lunch, Cholesterol, American Heart, Dietary supplement

Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.

Key Points: 
  • Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.
  • Beyond Crumbles’ strong nutritional profile, coupled with its simple and clean ingredient list, earned the product certification by the American Heart Association’s Heart-Check program and the American Diabetes Association’s Better Choices for Life program,” said Beyond Meat Founder and CEO Ethan Brown.
  • As part of Beyond Meat’s commitment to innovating for human health, this announcement follows Beyond Steak’s earlier certifications by the American Heart Association and the American Diabetes Association .
  • With 1.2 million Americans diagnosed with diabetes every year , the Better Choices for Life Program uses the American Diabetes Association’s evidence-based guidelines to help consumers make informed choices about the foods they purchase.

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Critical Care Medicine (journal), PAP, Pulmonary alveolar proteinosis, AJRCCM, Abstract, American Journal, Conference, APAP, Diagnosis

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.

Key Points: 
  • The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.
  • For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php .
  • Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
    Bruce Trapnell, M.D., M.S.
  • will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

Retrieved on: 
Wednesday, March 20, 2024
IOP, Ocular hypertension, Professor, NCX, Patient, American Journal, American Journal of Ophthalmology, Glaucoma, Vision science, Intraocular pressure, Pharmaceutical industry

Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025

Key Points: 
  • Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
  • “The data from the Mont Blanc Phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali Phase 3 trial, expected in H2 2025.
  • The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points.
  • With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”

Vizient Task Force Releases Recommendations for Hospitals on Preparing for an Active Shooter Event

Retrieved on: 
Tuesday, April 2, 2024
Science, Public Policy, Government, Practice Management, Research, Medical Supplies, Health, Law Enforcement, Emergency Services, Hospitals, Organization, Communication, Disaster medicine, Risk, Patient, American Journal, Hospital, Trauma, Hope, Bleeding, Hospice and palliative medicine, Safety, Language, Risk management

Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.

Key Points: 
  • Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.
  • The recommendations were made by a task force of 40 Vizient network executives from 27 organizations across the country.
  • The recommendations and rationales bring attention to organizational tactics that were found by the task force to be lacking or inconsistent.
  • “It is an uncomfortable topic to discuss but it is vital that hospitals address the issue of a potential active shooter event,” said Susan Chishimba, Vizient Member Networks senior director.

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

Retrieved on: 
Tuesday, April 2, 2024
Annals of Emergency Medicine, Veteran, Headache (journal), Headache, Patient, American Journal, Emergency medicine, McMaster University, University, Software, Migraine, OTC, Ohio State University, Multimedia, University of Toronto, FDA, Food, Medical device

Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.

Key Points: 
  • Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.
  • HeadaTerm 2 is a testament of WAT Medical's continued commitment to providing safe, effective, and user-friendly innovative medical devices at the most competitive price.
  • It provided an affordable solution to a debilitating condition that affects nearly 40 million people in the U.S. HeadaTerm 2 is a rechargeable device that features adjustable intensity setting and will be the most affordable device of its kind.
  • HeadaTerm 2 will appear at the 66th Annual Scientific Meeting in June 2024 hosted by American Headache Society.

POSSIBLE TEAMS UP WITH NBCUNIVERSAL FOR ON-SITE HOSTING DUTIES

Retrieved on: 
Monday, April 1, 2024
Universe, MTV, WRIC-TV, Latin American Music Awards, VIP, POV, Real Simple, Creativity, Marketing, Ali Baba, TechCheck, NBCUniversal, Television, Fontainebleau Miami Beach, Shaq Vs., ESPN, WPLG-TV, TLC, Woman, Pulse, CBS Evening News, Emmy Awards, Cold Pizza, Weather, ABC, American Music Awards, Access Hollywood, Road Rules, American Journal, CNBC, News, ESPN2, Fox News, CBS, Kit Hoover, Culture, Name, Real Life, Constance Jones, Silicon, Atmosphere, Dream Job, Growth, WeWork, Billboard Latin Music Awards, Entertainment

NEW YORK, April 1, 2024 /PRNewswire/ -- Beyond Ordinary Events, Inc. and POSSIBLE, the premier marquee marketing event, announced today Access Hollywood's Kit Hoover, Telemundo's Jessica Carrillo, and NBC6 News' Constance Jones are the newest hosts to join the anticipated lineup of speakers and leaders at POSSIBLE.

Key Points: 
  • The Vision Hall is where business leaders come to ignite the industry's imagination and spark interesting discussions about the future of marketing.
  • "Kit, Jessica, and Constance will be vital assets to our team of hosts at POSSIBLE.
  • From their experience, they have their finger on the pulse of the cultural zeitgeist, making them in tune to all things POSSIBLE."
  • During the event, POSSIBLE will present 14 tracks of curated content, masterclasses, workshops, an exposition, an outside activation area, VIP networking, and entertainment.

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
Thursday, March 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

Dr. Rachel Hardeman, Renowned Reproductive Health Equity Researcher, Joins Maven Clinic as Visiting Scientist

Retrieved on: 
Wednesday, March 27, 2024
Racism, Gynaecology, Public health, Health equity, Family, CLAS, American Journal, Public, Mental health, Research, Prenatal care, HHS, Black, University, Pregnancy, Multiracial people, Woman, Community advisory board, Publication, Data collection, Blue Cross, Workforce, Medical device

NEW YORK, March 27, 2024 /PRNewswire/ -- Maven Clinic, the world's largest virtual clinic for women's and family health, today announced the appointment of Dr. Rachel Hardeman, a nationally recognized reproductive health equity researcher, as Maven's newest Visiting Scientist. As part of its commitment to driving equitable health outcomes for women and families, Maven also announced that it has established a Community Advisory Board and formalized a Culturally and Linguistically Appropriate Services (CLAS) program aligned to the Department of Health and Human Services (HHS) standards for health equity.

Key Points: 
  • NEW YORK, March 27, 2024 /PRNewswire/ -- Maven Clinic , the world's largest virtual clinic for women's and family health, today announced the appointment of Dr. Rachel Hardeman, a nationally recognized reproductive health equity researcher, as Maven's newest Visiting Scientist.
  • Her findings have appeared in publications such as the New England Journal of Medicine and the American Journal of Public Health.
  • She currently serves as the first ever Blue Cross Endowed Professor of Health and Racial Equity at the University of Minnesota.
  • It also includes commitments to workforce development, ensuring that 100% of Maven front-line staff receive comprehensive training in health equity.